What We're Reading: Page 111
Industry reads hand-picked by our editors
Jul 19, 2022
-
The Boston Business Journal
Biogen's Mass. headcount falls by 300 in 10 months
-
The Boston Globe
More lab space: French pharma Servier is growing its cancer business in Seaport
-
Evaluate Vantage
Unpacking Royalty Pharma
-
Reuters
As COVID patent war rages on, pharma group seeks fairer future access
Jul 18, 2022
-
The Wall Street Journal
Merck Deal for Seagen Seen as Unlikely by Earnings Release
-
Stat News
Biotech executives pull in some of health care's biggest paydays
-
Kaiser Health News
FTC Official: Antitrust Push in Health Care Must Focus on a Merger’s ‘Human Impact’
Jul 15, 2022
-
Kaiser Health News
As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger
-
Reuters
After bruising year, GSK approaches consumer split in better health
-
Politico
Manchin rejects climate, tax elements of party-line Dem bill
-
Bloomberg
Chinese Cancer Drugs Biotech Cstone Pharmaceuticals Considers Sale
Jul 14, 2022
Jul 13, 2022
Jul 12, 2022
-
Bloomberg Law
Drug Pricing Plan Faces Industry Gripes as Senate Reconvenes
-
Associated Press
Over-the-counter birth control? Drugmaker seeks FDA approval
-
Evaluate Vantage
Are we there yet?
-
Healthcare Dive
Tracking state abortion bans in the US
Jul 11, 2022
-
The New York Times
The U.S. May Be Losing the Fight Against Monkeypox, Scientists Say
-
Chemical & Engineering News
UK government chaos yields uncertainty for scientists
-
Fierce Biotech
Sanofi preps hemophilia duo for patients seeking as 'normal a life as possible'
-
Reuters
EU recommends second COVID booster for over-60s
Previous
